Evidence map›Paper›PMID 38366223›Full record

ArticleNature nanotechnology2024

Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent.

Revadee Liam-Or, Farid N Faruqu, Adam Walters, Shunping Han, Lizhou Xu, Julie Tzu-Wen Wang, Jennifer Oberlaender, Alberto Sanchez-Fueyo, Giovanna Lombardi, Francesco Dazzi and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Nature nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 1 pooled it
33.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 3 countries.

Revadee Liam-OrInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Farid N FaruquInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK.ORCID http://orcid.org/0000-0001-5718-0039
Adam WaltersInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Shunping HanInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Lizhou XuInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK.ORCID http://orcid.org/0000-0001-5983-4059
Julie Tzu-Wen WangInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK.ORCID http://orcid.org/0000-0001-5956-0123
Jennifer OberlaenderMax Planck Institute for Polymer Research, Mainz, Germany.
Alberto Sanchez-FueyoInstitute of Liver Studies, King's College London University and King's College Hospital, London, UK.
Giovanna LombardiPeter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
Francesco DazziComprehensive Cancer Centre, King's College London, London, UK.
Volker MailaenderMax Planck Institute for Polymer Research, Mainz, Germany.ORCID http://orcid.org/0000-0001-6583-8136
Khuloud T Al-JamalInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK. khuloud.al-jamal@kcl.ac.uk.ORCID http://orcid.org/0000-0001-5165-2699
King's College London · GBJohannes Gutenberg University Mainz · DE

Funding

Brain Tumour Charity GN-000398RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/J008656/1Wellcome TrustWellcome Trust (Wellcome) WT103913
6 · The paper itself

Abstract

Extracellular vesicles (EVs) derived from mesenchymal stem cells are promising nanotherapeutics in liver diseases due to their regenerative and immunomodulatory properties. Nevertheless, a concern has been raised regarding the rapid clearance of exogenous EVs by phagocytic cells. Here we explore the impact of protein corona on EVs derived from two culturing conditions in which specific proteins acquired from media were simultaneously adsorbed on the EV surface. Additionally, by incubating EVs with serum, simulating protein corona formation upon systemic delivery, further resolved protein corona-EV complex patterns were investigated. Our findings reveal the potential influences of corona composition on EVs under in vitro conditions and their in vivo kinetics. Our data suggest that bound albumin creates an EV signature that can retarget EVs from hepatic macrophages. This results in markedly improved cellular uptake by hepatocytes, liver sinusoidal endothelial cells and hepatic stellate cells. This phenomenon can be applied as a camouflage strategy by precoating EVs with albumin to fabricate the albumin-enriched protein corona-EV complex, enhancing non-phagocytic uptake in the liver. This work addresses a critical challenge facing intravenously administered EVs for liver therapy by tailoring the protein corona-EV complex for liver cell targeting and immune evasion.

Indexed as

Extracellular VesiclesMesenchymal Stem CellsProtein CoronaAnimalsHepatocytesHumansLiverMacrophagesMiceProtein Corona

Identifiers

PMID38366223
PMCPMC11186763
OpenAlexW4391882866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.